The IPO market came back full force this week following the July 4th pause. Nine deals raised a combined $931 million, averaging a gain of 29%. Five biotechs went public, including top performer Allakos, which finished the week up 95%. Tilray grabbed...read more
Allakos, which is developing antibodies for allergic, inflammatory and proliferative diseases, raised $128 million by offering 7.1 million shares at $18, above the $15 to $17 range. The company originally planned to offer 6.0 million shares. Insiders...read more
There are 10 IPOs expected to price this week after the July holiday slowdown. The week is being led by oil and gas OEM AFG Holdings and Canadian cannabis supplier Tilray. Six...read more
After a short holiday break, the IPO market has resumed being on fire. 11 deals launched their offerings. 10 are on the calendar for next week, including 7 that plan to...read more
US IPO Weekly Recap: Bud, biotechs, banks and breast implants make gains in 9-IPO week
The IPO market came back full force this week following the July 4th pause. Nine deals raised a combined $931 million, averaging a gain of 29%. Five biotechs went public, including top performer Allakos, which finished the week up 95%. Tilray grabbed...read more
Immunotherapy biotech Allakos prices upsized IPO above the range at $18
Allakos, which is developing antibodies for allergic, inflammatory and proliferative diseases, raised $128 million by offering 7.1 million shares at $18, above the $15 to $17 range. The company originally planned to offer 6.0 million shares. Insiders...read more
US IPO Week Ahead: 10 US IPOs planned for the week of July 16
There are 10 IPOs expected to price this week after the July holiday slowdown. The week is being led by oil and gas OEM AFG Holdings and Canadian cannabis supplier Tilray. Six...read more
The IPO market has resumed being on fire with 11 new deals
After a short holiday break, the IPO market has resumed being on fire. 11 deals launched their offerings. 10 are on the calendar for next week, including 7 that plan to...read more